Pharmacokinetics and Drug–Drug Interactions of Novel Psychotropic Drugs

Dear Colleagues,

Psychotropic drugs (antipsychotics, antidepressants, mood stabilizers, anxiolytics) have been playing an increasing role in the treatment of mental disorders for over half a century. They have offered substantial relief from some debilitating symptoms like auditory hallucinations, depression, and excessive mood fluctuations. Psychotropics are used as monotherapy, as well as adjunctive or augmentation therapy in several psychiatric disorders. Pharmacotherapy with psychotropic drugs is carried out for months/years, very often in combination with drugs from other pharmacological groups. Concomitant therapy with psychotropics may result in pharmacokinetic interactions that produce adverse reactions. The majority of clinically relevant pharmacokinetic drug–drug interactions with psychotropics occur as a consequence of drug-induced changes in hepatic metabolism. The most frequently reported cases of drug–drug interactions include the modulation of psychotropic drugs on drug-metabolizing enzymes and transporters and the causative pharmacokinetic effect of co-administered therapeutic drugs that are substrates for drug-metabolizing enzymes and transporters.

Therefore, this Special Issue aims to highlight the pharmacokinetics and drug interactions of novel psychotropic drugs and their mechanistic understanding concerning drug-metabolizing enzymes and drug transporters.

In this Special Issue of Pharmaceutics, we invite you to contribute original research articles or reviews on all aspects of the theme “Pharmacokinetics and Drug–Drug Interactions of Novel Psychotropic Drugs”. Expert articles describing new aspects of pharmacokinetics, ADME, drug–drug interactions, or new aspects of novel psychotropic drug actions are highly welcome.

Dr. Przemysław J. Danek
Dr. Anna Haduch
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.